JOHNSON & JOHNSON
Close on Oct 19, 2026
- Market cap
- $619.27B
- P/E (TTM)
- 29.4
- Dividend yield
- 2.03%
About Johnson & Johnson
Pharmaceutical Preparations, SIC 2834
Johnson & Johnson is a healthcare holding company that researches, develops, and manufactures products focused on human health and well-being. The company operates through two main business segments: Innovative Medicine and MedTech. Its Innovative Medicine division focuses on therapeutic areas including oncology, immunology, neuroscience, infectious diseases, cardiovascular and metabolism, and pulmonary hypertension. Its MedTech segment provides products and technologies for cardiovascular care, orthopaedics, surgery, and vision care. Products are distributed to retailers, wholesalers, hospitals, clinics, and healthcare professionals for patient and surgical use.
Operating companies under Johnson & Johnson conduct business across virtually all countries globally. The company's subsidiaries operate 63 manufacturing facilities alongside thousands of external suppliers worldwide. In 2025, employees across 73 countries participated in its annual survey. The organization employs approximately 138,200 full-time equivalent personnel worldwide and maintains its corporate incorporation in the State of New Jersey.
Summary of the business section of Johnson & Johnson's latest annual report, written by StockData.
Company profile
Company
- Legal name
- JOHNSON & JOHNSON
- Founded
- 1887
- Headquarters
- New Brunswick, NJ
- Address
- One Johnson & Johnson Plz 08933
- Phone
- (732) 524-2455
- Website
- jnj.com
- Employees
- 138,200, Dec 28, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- New Jersey
- Fiscal year ends
- January 3
- Auditor
- PricewaterhouseCoopers LLP, Florham Park, New Jersey
Stock & identifiers
- Ticker
- JNJ
- Exchange
- NYSE
- Shares outstanding
- 2.41B, Jul 17, 2026
- Public float
- $367.00B, Jun 29, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Jun 13, 2001; 2-for-1, Jun 12, 1996; 2-for-1, Jun 10, 1992; 2-for-1, May 11, 1989; 3-for-1, May 19, 1981; 3-for-1, May 18, 1970; 3-for-1, Jun 19, 1967
- SEC CIK
- 200406
- CUSIP
- 478160104
- ISIN
- US4781601046
- LEI
- 549300G0CFPGEF6X2043
- EIN
- 22-1024240
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Joaquin Duato | CEO and Chairman of the Board, Director | 307,837 |
| Timothy Schmid | EVP, WW Chair, MedTech | 48,778 |
| Thomas Cavanaugh | EVP WW Chair, Innovative Med. | 499 |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | 209,451 |
| Elizabeth Forminard | EVP, Chief Legal Officer | 23,568 |
| Vanessa Broadhurst | EVP, Global Corp Affairs | 23,003 |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | 124,659 |
| John C. Reed | EVP, Innovative Medicine, R&D | 35,913 |
| Robert J. Decker | VP Corporate Controller | 28,537 |
| Joseph J. Wolk | Exec VP, CFO | 109,969 |
| James D. Swanson | EVP, CIO | 46,219 |
| Kristen Mulholland | EVP, Chief HR Officer | 19,678 |
| Eugene A. Woods | Director | 250 |
| Marillyn A. Hewson | Director | 3,000 |
| Daniel E. Pinto | Director | 0 |
| John G. Morikis | Director | 1,849 |
| Hubert Joly | Director | 5,000 |
| Mark B. McClellan | Director | – |
| Mary C. Beckerle | Director | – |
| Mark A. Weinberger | Director | 1,000 |
| Paula A. Johnson | Director | 191 |
| Nadja West | Director | – |
| Jennifer A. Doudna | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 J. Duato | $32.76M | $68.28M | $12.50M | $152 | $189 |
| FY2024 J. Duato | $24.30M | $16.98M | $11.24M | $103 | $148 |
| FY2023 J. Duato | $28.40M | $13.84M | $12.49M | $108 | $137 |
| FY2022 J. Duato | $13.10M | $18.91M | $8.02M | $118 | $137 |
| FY2021 J. Duato | $26.74M | $39.42M | $12.50M | $111 | $126 |
| FY2020 J. Duato | $29.58M | $28.99M | $12.95M | $111 | $108 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“Johnson & Johnson and its subsidiaries (the Company) have approximately 138,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field.”
Corporate history
Events identified from SEC filings